Abbott Laboratories (NYSE:ABT) Given Consensus Recommendation of “Buy” by Brokerages
Abbott Laboratories (NYSE:ABT) has earned an average rating of “Buy” from the eighteen analysts that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and twelve have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $87.94.
A number of brokerages have recently issued reports on ABT. Zacks Investment Research downgraded shares of Abbott Laboratories from a “buy” rating to a “hold” rating and set a $93.00 price target for the company. in a report on Wednesday, August 21st. ValuEngine downgraded shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. William Blair restated an “underperform” rating on shares of Abbott Laboratories in a report on Thursday, October 17th. Raymond James cut their price target on shares of Abbott Laboratories from $93.00 to $90.00 and set an “outperform” rating for the company in a report on Monday, October 14th. Finally, Credit Suisse Group raised their price target on shares of Abbott Laboratories from $95.00 to $98.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th.
In related news, SVP Randel William Woodgrift sold 21,000 shares of Abbott Laboratories stock in a transaction that occurred on Wednesday, October 23rd. The shares were sold at an average price of $80.54, for a total value of $1,691,340.00. Following the completion of the sale, the senior vice president now owns 68,562 shares in the company, valued at approximately $5,521,983.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.70% of the stock is currently owned by company insiders.
Shares of NYSE ABT traded down $0.94 during midday trading on Wednesday, reaching $84.51. 3,795,770 shares of the stock were exchanged, compared to its average volume of 5,291,160. The company has a 50 day simple moving average of $83.06 and a 200 day simple moving average of $82.98. The stock has a market capitalization of $151.11 billion, a P/E ratio of 29.34, a PEG ratio of 2.47 and a beta of 1.12. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.12 and a current ratio of 1.54. Abbott Laboratories has a twelve month low of $65.44 and a twelve month high of $88.76.
Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, October 16th. The healthcare product maker reported $0.84 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.84. The business had revenue of $8.08 billion during the quarter, compared to the consensus estimate of $8.10 billion. Abbott Laboratories had a net margin of 10.50% and a return on equity of 17.65%. The business’s revenue was up 5.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.75 EPS. On average, research analysts expect that Abbott Laboratories will post 3.24 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Friday, November 15th. Investors of record on Tuesday, October 15th were issued a $0.32 dividend. The ex-dividend date was Friday, October 11th. This represents a $1.28 annualized dividend and a yield of 1.51%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 44.44%.
Abbott Laboratories Company Profile
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.
See Also: What is Green Investing?
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.